Neuraxis, Inc. NRXS 深 沪
等待开盘 12-19 09:30:00 美东时间
2.88
+0.120
+4.35%
华盛通- 最 高3.01
- 今 开2.73
- 成交量 9.06万股
- 最 低 2.73
- 昨 收 2.76
- 总市值 2843.37万
- 52周最高 6.20
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 1.33
- 委 比 0.00%
- 总股本 987.28万
- 历史最高 6.93
- 量 比 2.18
- 振 幅 10.14%
- 历史最低 1.33
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 4 percent increase over losses of $(0.25) per share from the same
11-11 06:53
Neuraxis Earnings Preview
Neuraxis (AMEX:NRXS) is gearing up to announce its quarterly earnings on Tuesda...
11-11 00:03
NeurAxis Expands Stock Offering to $6.27 Million
NeurAxis, Inc. ( ($NRXS) ) has issued an announcement. NeurAxis, Inc. has recei...
10-24 20:48
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
NeurAxis has received FDA clearance for its PENFS technology to treat functional abdominal pain and nausea in patients aged 8 and older, marking the first FDA-approved treatment for adults with functional dyspepsia. This expansion includes a new CPT code effective January 1, 2026, enhancing its market reach and offering a non-invasive solution for patients with limited treatment options.
10-24 12:00
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
Nurix Therapeutics announced clinical data from the Phase 1a study of NX-1607, a first-in-class oral CBL-B inhibitor for treating advanced solid tumors. NX-1607 showed on-target immune activation and anti-tumor activity, including tumor biomarker reductions, tumor shrinkage, and partial responses in heavily pretreated patients. Results from 82 patients across 11 tumor types demonstrated dose-dependent activity, with a 49.3% disease control rate. ...
10-18 07:00
NeurAxis Enters Market Offering Agreement with Craig-Hallum
NeurAxis, Inc. ( ($NRXS) ) has provided an update. On August 29, 2025, Neuraxis...
09-02 21:52
Neuraxis Q2 EPS $(0.22) Beats $(0.23) Estimate, Sales $894.086K Miss $967.250M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 47.62 percent increase over losses of $(0.42) per share from the same
08-12 19:05
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
NeurAxis Inc. reported 2Q25 financial results with a 46% YoY revenue increase to $894K, operating expenses down 10% YoY, and a 22% improvement in operating loss. The company secured FDA clearance for expanded uses of its IB-Stim therapy for pediatric conditions and received a new CPT code for 2026. Cash balance reached $6M following a $5M equity融资 round. With strong unit sales growth and expanded insurance coverage, NeurAxis remains confident in ...
08-12 11:00
Earnings Outlook For Neuraxis
Neuraxis (AMEX:NRXS) is preparing to release its quarterly earnings on Tuesday,...
08-12 02:03
